Literature DB >> 10077052

Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome.

T A Sohn1, K D Lillemoe, J L Cameron, H A Pitt, J J Huang, R H Hruban, C J Yeo.   

Abstract

OBJECTIVE: This single-institution experience retrospectively reviews the outcomes of patients undergoing reexploration for periampullary carcinoma at a high-volume center. SUMMARY BACKGROUND DATA: Many patients are referred to tertiary centers with periampullary carcinoma after their tumors were deemed unresectable at previous laparotomy. In carefully selected patients, tumor resection is often possible; however, the perioperative results and long-term outcome have not been well defined.
METHODS: From November 1991 through December 1997, 78 patients who underwent previous exploratory laparotomy and/or palliative surgery for suspected periampullary carcinoma underwent reexploration. The operative outcome, resectability rate, pathology, and long-term survival rate were compared with 690 concurrent patients who had not undergone previous exploratory surgery.
RESULTS: Fifty-two of the 78 patients (67%) undergoing reexploration underwent successful resection by pancreaticoduodenectomy; the remaining 26 patients (34%) were deemed to have unresectable disease. Compared with the 690 patients who had not undergone recent related surgery, the patients in the reoperative group were similar with respect to gender, race, and resectability rate but were significantly younger. The distribution of periampullary cancers by site in the reoperative group undergoing pancreaticoduodenectomy (n = 52) was 60%, 19%, 15%, and 6% for pancreatic, ampullary, distal bile duct, and duodenal tumors, respectively. These figures were similar to the 65%, 14%, 16% and 5% for resectable periampullary cancers found in the primary surgery group (n = 460). Intraoperative blood loss and transfusion requirements did not differ between the two groups. However, the mean operative time was 7.4 hours in the reoperative group, significantly longer than in the control group. On pathologic examination, reoperative patients had smaller tumors, and the percentage of patients with positive lymph nodes in the resection specimen was significantly less. The incidence of positive margins was similar between the two groups. Postoperative lengths of stay, complication rates, and perioperative mortality rates were not higher in reoperative patients. The long-term survival rate was similar between the two resected groups, with a median survival of 24 months in the reoperative group and 20 months in those without previous exploration.
CONCLUSIONS: These data demonstrate that patients undergoing reoperation for periampullary carcinoma have similar resectability, perioperative morbidity and mortality, and long-term survival rates as patients undergoing initial exploration. The results suggest that selected patients considered to have unresectable disease at previous surgery should undergo restaging and reexploration at specialized high-volume centers.

Entities:  

Mesh:

Year:  1999        PMID: 10077052      PMCID: PMC1191705          DOI: 10.1097/00000658-199903000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

1.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

2.  Reoperation for pancreatic cancer.

Authors:  A R Moossa
Journal:  Arch Surg       Date:  1979-04

3.  The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma.

Authors:  G Crile
Journal:  Surg Gynecol Obstet       Date:  1970-06

4.  Periampullary tumors: which ones should be resected?

Authors:  B A Jones; B Langer; B R Taylor; M Girotti
Journal:  Am J Surg       Date:  1985-01       Impact factor: 2.565

5.  Prognostic factors in bile duct carcinoma: analysis of 96 cases.

Authors:  R K Tompkins; D Thomas; A Wile; W P Longmire
Journal:  Ann Surg       Date:  1981-10       Impact factor: 12.969

6.  Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs Whipple resection in good risk patients.

Authors:  T M Shapiro
Journal:  Ann Surg       Date:  1975-12       Impact factor: 12.969

7.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.

Authors:  C J Yeo; J L Cameron; T A Sohn; K D Lillemoe; H A Pitt; M A Talamini; R H Hruban; S E Ord; P K Sauter; J Coleman; M L Zahurak; L B Grochow; R A Abrams
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

8.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Authors:  M H Kalser; S S Ellenberg
Journal:  Arch Surg       Date:  1985-08

9.  Carcinoma of the ampulla of Vater: long-term survival after surgical treatment.

Authors:  T C Wei; S C Yu; P H Lee; S C Hsu
Journal:  J Formos Med Assoc       Date:  1993-07       Impact factor: 3.282

10.  Adenocarcinoma of the duodenum: factors influencing long-term survival.

Authors:  T A Sohn; K D Lillemoe; J L Cameron; H A Pitt; H S Kaufman; R H Hruban; C J Yeo
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.267

View more
  11 in total

1.  Contemporary single-center surgical experiences in redo procedures of the pancreas: improved outcome and reduction of operative risk.

Authors:  Sabine Kersting; Monika Silvia Janot; Ansgar Michael Chromik; Dominique Suelberg; Waldemar Uhl; Matthias Hartmut Seelig
Journal:  J Gastrointest Surg       Date:  2010-11-12       Impact factor: 3.452

2.  Hospital readmission after pancreaticoduodenectomy.

Authors:  Dawn M Emick; Taylor S Riall; John L Cameron; Jordan M Winter; Keith D Lillemoe; Joann Coleman; Patricia K Sauter; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Reoperative surgery for chronic pancreatitis: is it safe?

Authors:  Thomas Schnelldorfer; David N Lewin; David B Adams
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

4.  Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection?

Authors:  Stefan Heinrich
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

5.  Resection of the celiac axis for invasive pancreatic cancer.

Authors:  Martin A Makary; Elliot K Fishman; John L Cameron
Journal:  J Gastrointest Surg       Date:  2005-04       Impact factor: 3.452

6.  Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival.

Authors:  Fengchun Lu; Kevin C Soares; Jin He; Ammar A Javed; John L Cameron; Neda Rezaee; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

7.  Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Jeffrey F Geschwind; Sally E Mitchell; Anthony C Venbrux; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2003-02       Impact factor: 3.452

8.  Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.

Authors:  R Krempien; M W Muenter; W Harms; J Debus
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

9.  Pancreatic redo procedures: to do or not to do -- this is the question.

Authors:  Matthias H Seelig; Ansgar M Chromik; Dirk Weyhe; Christophe A Müller; Orlin Belyaev; Ulrich Mittelkötter; Andrea Tannapfel; Waldemar Uhl
Journal:  J Gastrointest Surg       Date:  2007-09       Impact factor: 3.452

10.  Is Pancreaticoduodenectomy Feasible for Recurrent Remnant Bile Duct Cancer Following Bile Duct Segmental Resection?

Authors:  Jae Geun Lee; Sung Hwan Lee; Jin Hong Lim; Joon Seong Park; Dong Sup Yoon; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2015-09-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.